Nectar Lifesciences (NSE:NECLIFE) E10: ₹-2.28 (As of Mar. 2026)


NSE:NECLIFE Nectar Lifesciences Ltd NSE:NECLIFE
51 GF Score
Price ₹11.48
GF Value ₹6.86
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Nectar Lifesciences E10?

Nectar Lifesciences NSE:NECLIFE -2.30% 51 E10 is ₹-2.28 as of Mar. 2026. GuruFocus rates NSE:NECLIFE with a GF Score™ of 51/100 and a GF Value™ of ₹6.86 (Significantly Overvalued). The stock has 2 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Nectar Lifesciences's adjusted earnings per share data for the three months ended in Mar. 2026 was ₹-3.380. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is ₹-2.28 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2026-07-07), Nectar Lifesciences's current stock price is ₹11.48. Nectar Lifesciences's E10 for the quarter that ended in Mar. 2026 was ₹-2.28. Nectar Lifesciences's Shiller PE Ratio of today is .

During the past 13 years, the highest Shiller PE Ratio of Nectar Lifesciences was 211.89. The lowest was 120.95. And the median was 158.21.


Nectar Lifesciences  (NSE:NECLIFE) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

During the past 13 years, the highest Shiller P/E Ratio of Nectar Lifesciences was 211.89. The lowest was 120.95. And the median was 158.21.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Nectar Lifesciences E10 Related Terms


Nectar Lifesciences E10 Historical Data

* Premium members only.

The historical data trend for Nectar Lifesciences's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nectar Lifesciences E10 Chart

Nectar Lifesciences Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 -0.64 -2.28

Nectar Lifesciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.64 -1.02 -2.04 -1.90 -2.28

NSE:NECLIFE vs ZTS, UTHR: E10 Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Nectar Lifesciences's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nectar Lifesciences Shiller PE Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Nectar Lifesciences's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Nectar Lifesciences's Shiller PE Ratio falls into.


NSE:NECLIFE
51GF Score
Nectar Lifesciences Ltd NSE:NECLIFE
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nectar Lifesciences E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Nectar Lifesciences's adjusted earnings per share data for the three months ended in Mar. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-3.38/164.2724*164.2724
=-3.380

Current CPI (Mar. 2026) = 164.2724.

Nectar Lifesciences Quarterly Data

per share eps CPI Adj_EPS
201103 0.000 70.768 0.000
201203 0.000 76.889 0.000
201303 0.000 85.687 0.000
201403 0.000 91.425 0.000
201503 0.000 97.163 0.000
201603 0.000 102.518 0.000
201703 0.000 105.196 0.000
201803 0.000 109.786 0.000
201806 0.590 111.317 0.871
201809 0.260 115.142 0.371
201812 0.490 115.142 0.699
201903 0.780 118.202 1.084
201906 0.610 120.880 0.829
201909 0.110 123.175 0.147
201912 0.370 126.235 0.481
202003 0.330 124.705 0.435
202006 -0.750 127.000 -0.970
202009 -0.330 130.118 -0.417
202012 -0.360 130.889 -0.452
202103 -1.830 131.771 -2.281
202106 0.080 134.084 0.098
202109 0.080 135.847 0.097
202112 0.430 138.161 0.511
202203 0.510 138.822 0.603
202206 0.170 142.347 0.196
202209 -1.000 144.661 -1.136
202212 -0.410 145.763 -0.462
202303 0.160 146.865 0.179
202306 0.080 150.280 0.087
202309 0.050 151.492 0.054
202312 0.070 152.924 0.075
202403 0.020 153.035 0.021
202406 0.130 155.789 0.137
202409 -0.250 157.882 -0.260
202412 0.350 158.323 0.363
202503 -5.800 157.552 -6.047
202506 -2.820 159.755 -2.900
202509 -7.850 162.289 -7.946
202512 0.640 163.281 0.644
202603 -3.380 164.272 -3.380

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of ₹-2.28 mean?
Nectar Lifesciences (NSE:NECLIFE) has a E10 of ₹-2.28 as of Mar. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Nectar Lifesciences and its competitors.
Is Nectar Lifesciences' E10 too high?
Nectar Lifesciences' current E10 is ₹-2.28. Overall, Nectar Lifesciences has a GF Score™ of 51/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Nectar Lifesciences' E10 compare to ZTS and UTHR?
Nectar Lifesciences' E10 of ₹-2.28 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Drug Manufacturers company?
A good E10 depends on the Drug Manufacturers industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Nectar Lifesciences and its competitors. Nectar Lifesciences's current E10 is ₹-2.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nectar Lifesciences stock overvalued right now?
Based on GuruFocus' analysis, Nectar Lifesciences (NSE:NECLIFE) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹6.86, compared to a current price of ₹11.48 — trading 67.3% above its estimated fair value. The current E10 is ₹-2.28. Nectar Lifesciences' overall GF Score™ is 51/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Nectar Lifesciences (NSE:NECLIFE), the current E10 is ₹-2.28 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Nectar Lifesciences (NSE:NECLIFE) Overvalued in 2026?

Based on GuruFocus' analysis, Nectar Lifesciences stock appears to be overvalued. The current stock price of ₹11.48 is trading 67.3% above its estimated GF Value™ of ₹6.86. GuruFocus considers Nectar Lifesciences to be Significantly Overvalued.

Key valuation signals for NSE:NECLIFE:

  • E10: ₹-2.28
  • GF Value™: ₹6.86 vs. price of ₹11.48 (67.3% above fair value)
  • GF Score™: 51/100 with 2 warning signs

No single metric tells the full story. See the NSE:NECLIFE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Nectar Lifesciences Business Description

Other Exchanges 532649:India
Address S.C.O. 38-39, Sector 9-D, B-1011/1012, 10th Floor NAURANG HOUSE, Chandigarh, IND, 160009
Nectar Lifesciences Ltd is an India-based pharmaceutical company specializing in Cephalosporins. It is engaged in manufacturing specialized pharmaceutical intermediates, active pharmaceutical ingredients (APIs), and finished dosage formulations. It operates in the business segment of Pharmaceuticals Products. The Company is also in the Menthol business and succeeded in both domestic and international markets. Its business areas are APIs, Formulations, and Empty Hard Gelatin Capsules. Geographically, it derives a majority of its revenue from India.
51GF Score

Get the complete analysis for NSE:NECLIFE

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹11.48
Price
₹6.86
GF Value